Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.52 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CTH | P32929 | 1/20 | 0.44 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6166204 | 1.00 | NR4A1 (0.53) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL213146 | 0.98 | NR4A1 (0.55) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL213145 | 0.98 | NR4A1 (0.55) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL215448 | 0.79 | NR4A1 (0.52) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL215449 | 0.79 | NR4A1 (0.52) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL878896 | 0.78 | NR4A1 (0.55) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL840812 | 0.78 | NR4A1 (0.50) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL862025 | 0.78 | NR4A1 (0.50) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL215884 | 0.78 | NR4A1 (0.50) | NR4A1MAOAMEN1NPC1RAB9A | |
| SCHEMBL9085905 | 0.76 | MAOA (0.55) | NR4A1MAOAMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101157685-A | Synthesis of 4-(piperidyl)(2-pyridyl)methanone-(e)-o-methyloxime and salts | SCHERING CORP (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-100360520-C | Synthesis of 4- (piperidinyl) (2-pyridinyl) methylene- (E) -O-methyloxime and salts thereof | SCHERING CORP (US) | 2008-01-09 | — | — | CN | disclosed |
| CN-1678605-A | Synthesis of 4- (piperidinyl) (2-pyridinyl) methylene- (E) -O-methyloxime and salts thereof | SCHERING CORP (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1436282-B1 | SYNTHESIS OF 4-(PIPERIDYL) (2-PYRIDYL)METHANONE-(E)-O-METHYLOXIME AND ITS SALTS | SCHERING CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1436282-B1 | SYNTHESIS OF 4-(PIPERIDYL) (2-PYRIDYL)METHANONE-(E)-O-METHYLOXIME AND ITS SALTS | SCHERING CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1436282-A1 | SYNTHESIS OF 4-(PIPERIDYL) (2-PYRIDYL)METHANONE-(E)-O-METHYLOXIME AND ITS SALTS | SCHERING CORPORATION (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6642385-B2 | Producing high purity stereoisomer; forming grignard derivative of 4-halo-piperidine carbamate and coupling with 2-cyanopyridine; oximination with alkyl chloroformate; hydrolyzing to free base | SCHERING CORPORATION | 2003-11-04 | — | — | US | disclosed |
| US-20030105136-A1 | Synthesis of 4-(piperidyl)(2-pyridyl)methanone-(E)-O-methyloxime and salts | SCHERING CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20030105136-A1 | Synthesis of 4-(piperidyl)(2-pyridyl)methanone-(E)-O-methyloxime and salts | SCHERING CORPORATION | 2003-06-05 | — | — | US | disclosed |
| WO-2003033488-A1 | SYNTHESIS OF 4-(PIPERIDYL) (2-PYRIDYL)METHANONE-(E)-O-METHYLOXIME AND ITS SALTS | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105136-A1 | Synthesis of 4-(piperidyl)(2-pyridyl)methanone-(E)-O-methyloxime and salts | DNMT1, PAM, TET2 | MAOA 1387/4885MAOB 914/4885TOP2A 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.